Polycythaemia Vera

Shaping your forecasting.

Welcome to theHub

Polycythaemia Vera

Polycythaemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, Osler disease, primary polycythemia, polycythemia rubra vera or Vaquez disease, is the over production of red blood cells as a result of acquired mutations in an early blood-forming cell.

Read More about Polycythaemia Vera

Since these early blood-forming cells have the capability to form not only red cells, but also white cells and platelets, any combination of these cell lines may be affected. This condition develops slowly and may remain undetected for many years. Main symptoms and co-morbidities for Polycythemia Vera include:

Blood clots
Splenomegaly
Skin problems
Peptic Ulcers
Gout
Myelofibrosis
Myelodysplastic syndrome
Acute myeloid leukaemia

Epidemiology Data

Data Available: Prevalence Data

Data covers: Males and Females (where applicable) from 2010 to 2050.

Data is split into 5 year age ranges (0-4, 5-9 etc) from 0 to 100+ years, across multiple countries.

Additional sub filters of the data are available. Please see the below pop up box for more information.

Once purchased, the data will be provided in an embedded PowerBI document, in which the data can be filtered and viewed in a way which suits your needs. Raw data can also be downloaded. Below is an example embedded data set which can be filtered in a similar way.

Instructions:
Once the data set has been purchased, please refresh this page. The example data set will then be replaced with actual data.

Please contact us for further information regarding filtering of the data, viewing the data, data available, custom quotes, or anything else.

Read More about the Data Filters available within the Epi Data

As well as prevalence, data can be filtered by the following attributes:
• Aspirin therapy
• Chronic heart failure
• Cytoreductive drug exposure
• Erythromelalgia
• Hypertension
• Incident acute leukaemia
• Incident thrombosis : Sub set (Thrombosis outcome Fatal, Thrombosis outcome Non-fatal)
• Intermittent claudication
• JAK2-V617F mutation
• Myelofibrosis (SMF)
• Packed cell volume (L/L)
• Splenomegaly
• Thrombotic event history No prior thrombosis
• Thrombotic event history Prior thrombosis : Sub set (Prior arterial thrombosis, Prior venous thrombosis)

Further sub sets are available within the data. Please contact us for more information.

Countries Covered

Argentina
Australia
Austria
Belgium
Brazil
Canada
China
Czech Republic
Denmark
Finland
France
Germany
India
Ireland
Italy
Japan
Mexico
Netherlands
Norway
Poland
Portugal
Republic of Korea
Russian Federation
Spain
Sweden
Switzerland
Turkey
United Kingdom
United States of America

The more you buy, the more you save*

View cart

*discount added at checkout

For all your pharmaceutical
forecasting needs.

theHub is a portal of resources to help you create better forecasting. Courses, templates, software, data and working model examples to get you on the path to better forecasting. Sign up now to get access to a world of interactive content.

About J+D Forecasting.

At J+D it's our mission to simplify the complex nature of pharmaceutical forecasting to help support informed decision making for the future. We are dedicated to helping pharmaceutical and biotech companies use intelligent forecasting solutions to make strategic and operational investment decisions.

For decades, we have crafted bespoke pharmaceutical forecasting models, innovative software and interactive training solutions, each of which has been designed with client needs in mind, allowing businesses to create more intelligent and consistent insights.